<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2901">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01465022</url>
  </required_header>
  <id_info>
    <org_study_id>03-151</org_study_id>
    <nct_id>NCT01465022</nct_id>
  </id_info>
  <brief_title>Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial</brief_title>
  <official_title>Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Obstetricians and Gynecologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives

      To clarify the relationship between postpartum (2 weeks) use of progestin-only vs. combined
      oral contraceptive pills and the outcomes of breastfeeding continuation, infant growth,
      contraceptive method continuation, and pregnancy rates in breastfeeding women. Specific
      research questions:

        1. To determine whether there is a difference in rates of breastfeeding continuation at 2
           months and 4 months between postpartum breastfeeding women using progestin-only pills
           vs. combined pills.

        2. To determine whether there is a difference in infant growth at 2 months and 4 months
           between postpartum breastfeeding women using progestin-only pills vs. combined pills.

        3. To determine whether there is a difference in birth control method continuation at 2
           months and 4 months between postpartum breastfeeding women using progestin-only pills
           vs. combined pills.

        4. To determine whether there are differences in pregnancy rates between the two groups
           over the time course of the study.

      Hypothesis

      Combined oral contraceptive pills, when initiated by postpartum breastfeeding women, will
      cause a differential in continuation of breastfeeding: 35% continuation in the combined pill
      group vs. 60% in the progestin-only pill group at 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants Who Continued to Breastfeed at 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of participants who are continuing to breastfeed at 8 weeks after delivery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Breast Feeding</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Study Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study Arm A is one of two interventions (Combined estrogen-progestin pill)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study Arm B is one of two interventions (Progestin-only pill)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined estrogen-progestin pill</intervention_name>
    <description>1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo</description>
    <arm_group_label>Study Arm A</arm_group_label>
    <other_name>OCP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progestin-only pill</intervention_name>
    <description>.35 mg norethindrone once a day orally</description>
    <arm_group_label>Study Arm B</arm_group_label>
    <other_name>POP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  able to give informed consent

          -  postpartum women delivering at the University of New Mexico Hospital

          -  Intend to breastfeed

          -  Plan to use oral contraceptives as her family planning method

          -  Willing to be randomized to either progestin-only pills or combined pills

        Exclusion Criteria:

          -  medical contraindications to combined pills including history of thromboembolism,
             uncontrolled hypertension or complex migraine headaches

          -  preterm birth (&lt;37 weeks)

          -  small for gestational age infant (&lt;2500 grams)

          -  large for gestational age infant (&gt;4500 grams)

          -  infant with major congenital anomaly
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eve Espey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNM OB Gyn</affiliation>
  </overall_official>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 2, 2015</lastchanged_date>
  <firstreceived_date>November 1, 2011</firstreceived_date>
  <firstreceived_results_date>May 29, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Eve Espey</investigator_full_name>
    <investigator_title>Professor, OB-GYN</investigator_title>
  </responsible_party>
  <keyword>Breastfeeding rates</keyword>
  <keyword>Contraceptive continuation</keyword>
  <keyword>Birth control pills</keyword>
  <keyword>Lactation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study design is double-blind randomized controlled trial in which postpartum women who have decided to breastfeed and who choose birth control pills as their contraceptive method are randomized to one of two groups:</recruitment_details>
      <pre_assignment_details>The research nurse recruiting the eligible subject will ask the subject if they have been given adequate time to make a decision regarding study participation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combined Estrogen-progestin Pill</title>
          <description>Study Arm A is one of two interventions.</description>
        </group>
        <group group_id="P2">
          <title>Progestin-only Pill</title>
          <description>Study Arm B is one of two interventions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Breastfeeding discontinuation before 8 w</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Arm A</title>
          <description>Study Arm A is one of two interventions (OCP).</description>
        </group>
        <group group_id="B2">
          <title>Study Arm B</title>
          <description>Study Arm B is one of two interventions (POP).</description>
        </group>
        <group group_id="B3">
          <title>Not Randomized</title>
          <description>70 women who were enrolled.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="64"/>
                <measurement group_id="B2" value="63"/>
                <measurement group_id="B3" value="70"/>
                <measurement group_id="B4" value="197"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="64"/>
                <measurement group_id="B2" value="63"/>
                <measurement group_id="B3" value="70"/>
                <measurement group_id="B4" value="197"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="23.8" spread="4.4"/>
                <measurement group_id="B2" value="25.0" spread="5.4"/>
                <measurement group_id="B3" value="23.4" spread="5.0"/>
                <measurement group_id="B4" value="24.4" spread="197"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="64"/>
                <measurement group_id="B2" value="63"/>
                <measurement group_id="B3" value="70"/>
                <measurement group_id="B4" value="197"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="64"/>
                <measurement group_id="B2" value="63"/>
                <measurement group_id="B3" value="70"/>
                <measurement group_id="B4" value="197"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Continued to Breastfeed at 8 Weeks</title>
        <description>Proportion of participants who are continuing to breastfeed at 8 weeks after delivery</description>
        <time_frame>8 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Study Arm A</title>
            <description>Study Arm A is one of two interventions (Combined estrogen-progestin pill)
Combined estrogen-progestin pill: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo</description>
          </group>
          <group group_id="O2">
            <title>Study Arm B</title>
            <description>Study Arm B is one of two interventions (Progestin-only pill)
Progestin-only pill: .35 mg norethindrone once a day orally</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Continued to Breastfeed at 8 Weeks</title>
            <description>Proportion of participants who are continuing to breastfeed at 8 weeks after delivery</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years - no adverse events reported</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Arm A</title>
          <description>Study Arm A is one of two interventions (Combined estrogen-progestin pill)
Combined estrogen-progestin pill: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo</description>
        </group>
        <group group_id="E2">
          <title>Study Arm B</title>
          <description>Study Arm B is one of two interventions (Progestin-only pill)
Progestin-only pill: .35 mg norethindrone once a day orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eve Espey MD, MPH, Principal Investigator</name_or_title>
      <organization>University of New Mexico</organization>
      <phone>505 272 6372</phone>
      <email>eespey@salud.unm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
